Alyeska Investment Group
BBIO icon

Alyeska Investment Group’s BridgeBio Pharma BBIO Stock Holding History

Alyeska Investment Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-102,785
Closed -$5.34M – 593
2025
Q3 		$5.34M Buy
102,785
+95,156
+1,247% +$4.64M 0.02% 451
2025
Q2 		$329K Buy
+7,629
New +$277K ﹤0.01% 530
2025
Q1 		– Sell
-940,415
Closed -$25.8M – 517
2024
Q4 		$25.8M Buy
+940,415
New +$24.3M 0.1% 231
2019
Q3 		– Sell
-65,154
Closed -$1.76M – 414
2019
Q2 		$1.76M Buy
+65,154
New +$1.78M 0.02% 328

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group's BBIO Position: Q4 2025 in Review

Alyeska Investment Group sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 102,785 shares — an estimated $5.34M sold.

Alyeska Investment Group first reported a position in BBIO in Q2 2019 and held it in 4 quarters. The position peaked at $25.8M in Q4 2024. 432 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • Alyeska Investment Group reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 102,785 BridgeBio Pharma shares in Q4 2025, an estimated $5.34M.
  • Alyeska Investment Group first reported a position in BridgeBio Pharma in Q2 2019 and held it in 4 quarters.
  • Alyeska Investment Group's BridgeBio Pharma position peaked at $25.8M in Q4 2024.
  • 432 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Alyeska Investment Group's 13F filing for Q4 2025, filed 13 Feb 2026.